What's Next: Upcoming Readouts in 2026 TRIUMPH-1 (pivotal obesity) on May 21, 2026 (up to -30.3% at 104 weeks), and TRIUMPH-2 and TRIUMPH-3 together on July 23, 2026 (-20.8% and -22.6% at 12 mg)
Pros: Free medication, medical monitoring, compensation for time, high-quality product Cons: You might receive placebo, strict eligibility criteria, time commitment (regular visits) How to find trials: ClinicalTrials.gov, Lilly Trial Guide 2
And what we're finding is even though the muscle mass or the total muscle may be going down, the quality of the muscle is improving because the fat is being removed from the muscle, and function where we're looking at it is starting to improve
Those medications are stronger and longer-lasting than your natural GLP-1 signal
What are the Ingredients of semaglutide
GLP-1 RAs impact cardiac myocytes in conditions such as myocardial infarction, heart failure preserved ejection fraction (HFpEF), and cardiomyopathy